Form 4 Filing for Estrella Immunopharma, Inc.

This filing details a transaction by Liu Cheng, CEO and Director of Estrella Immunopharma, Inc. On August 25, 2026, Mr. Cheng exercised 100,000 incentive stock options with an exercise price of $0.815 per share, acquiring 100,000 shares of Common Stock. The options were granted on October 30, 2024, under the Issuer's 2023 Omnibus Incentive Plan, with 25% immediately exercisable and the remainder vesting over 48 months. Following this transaction, Mr. Cheng directly beneficially owns 397,437 shares of Common Stock. The total number of shares owned after the transaction is 900,000. This transaction is reported on a Form 4.